ABT — Abbott Laboratories

Signals diverge as of 2026-09-13. The sell-side is clearly bullish - 32 Buy vs 9 Hold vs 0 Sell ratings, a $123.64 average target (~21% above the $101.96 price), $135 targets from firms like TD Cowen, and fresh catalysts (FDA approvals for the TactiFlex Duo dual-energy ablation catheter and Libre Duo glucose-ketone sensor, plus a Google Health partnership for the Lingo biowearable). The tape disagrees: -8.08% over one month, -5.89% over one week, RSI 33.57, and a price below every key moving average. Bullish fundamental narrative colliding with weak price action nets out to genuinely neutral sentiment.

Revenue has climbed steadily from ~$10.1B in Q3 2023 to $12.59B in Q2 2026, but the last two prints carry an acquisition boost: Q2 2026 revenue rose 13.0% YoY (vs Q1 2026's +7.8%), largely from Exact Sciences consolidation, while management's comparable-sales guidance is a more modest 6.5-7.5%. The GAAP profit trend looks like deceleration - operating margin fell to 14.2% in Q2 2026 from 18.4% in Q2 2025, and diluted EPS halved to $0.53 from $1.01 - but that is overwhelmingly acquisition amortization and integration charges, not organic erosion; on an adjusted basis management actually RAISED FY2026 EPS guidance to $5.45-$5.60. One caution: Q4 2024 shows $9.23B net income / $5.27 EPS, a one-time item that distorts every trailing YoY comparison and is why the reported PEG ratio is negative. Net read: organic growth is stable-to-accelerating, GAAP margins are temporarily compressed by deal accounting, and the reported decline is largely optical.

Mixed but roughly fair. As of 2026-09-13, at $101.96, the TTM P/E is 32.8x - a premium to the 5-year average of 29.0x - but that trailing EPS ($3.11) is depressed by Exact Sciences amortization, so the headline multiple overstates expensiveness. On the company's raised FY2026 adjusted EPS of ~$5.50 the forward P/E is only ~18.5x, and P/S of 3.79x sits BELOW the 5-year average of 4.91x. Trailing EV/EBITDA of 20.6x looks rich, but against forward EBITDA it is closer to 14-15x. Verdict: fairly valued - not the bargain the forward P/E implies, not as expensive as the trailing P/E suggests.

The market is struggling with Abbott's GAAP-to-adjusted bridge. Because reported EPS is being mechanically halved by acquisition accounting while cash generation stays robust (TTM FCF ~$7.9B, ~4.5% yield), the 32.8x trailing multiple makes ABT look far more expensive than the ~18.5x forward earnings power justifies. The setup: if integration synergies and cancer-diagnostics/CGM growth land as guided, the forward multiple should compress (price up or estimates up) - but if the market keeps anchoring on depressed GAAP EPS, the stock can stay range-bound. Watch the Q3 2026 report (projected Oct 14, 2026, consensus ~$1.38-$1.42) for evidence the adjusted-vs-GAAP gap is narrowing, and treat any further GAAP-driven selloff as a potential entry rather than a thesis-breaker.

Weak near-term momentum. As of 2026-09-13, RSI(14) was 33.57 - approaching but not yet at oversold - and the $101.96 price sat below all three key averages: -7.88% vs the SMA20, -3.18% vs the SMA50, and -3.68% vs the SMA200. The stock is down 5.89% in a week and 8.08% in a month, though still +15.62% over three months. Read: a name that ran up into mid-2026 and is now in a sharp pullback, sitting in the lower third of its 52-week range. Entry implication: RSI near 34 hints a near-term bounce is possible, but with price below every moving average there is no confirmed support; a patient buyer could scale in, while momentum buyers should wait for a reclaim of the SMA20.

• Interest rates / cost of capital: higher hurdle rates keep scrutiny on the $21B Exact Sciences deal and on the sustainability of Abbott's 50+ year dividend-growth streak.
• Sector rotation and procedure volumes: strong elective-procedure trends underpin double-digit electrophysiology and structural-heart growth, while ABT's low 0.586 beta makes it a defensive holding in risk-off tape.
• FX volatility: a large overseas revenue base exposes results to currency swings, a stated headwind in current guidance.
• Healthcare regulation/reimbursement: potential expanded reimbursement for non-insulin Type 2 diabetes biowearables is a meaningful swing factor; localized pricing pressure in diabetes care persists.
• Medtech consolidation/M&A cycle: large-cap device makers are consolidating, and successful Exact Sciences integration is the key swing - the deal roughly doubled long-term debt to $29.6B from $10.8B at end-2025.

• Q3 2026 earnings (projected Oct 14, 2026; consensus EPS ~$1.38-$1.42) - the first clear read on whether the Exact Sciences-adjusted earnings bridge improves.
• Commercial rollouts of the FDA-approved TactiFlex Duo dual-energy ablation catheter and the Libre Duo 10-day glucose-ketone biowearable sensor.
• Reimbursement decisions on non-insulin Type 2 diabetes biowearables, a potential volume catalyst for Libre/Lingo.
• Exact Sciences integration synergies and accelerated Cologuard / cancer-diagnostics growth.
• Annual dividend increase (typically late in the year), extending the 50+ year streak.

• Exact Sciences integration and leverage: long-term debt jumped to $29.6B in Q2 2026 from $10.8B at end-2025; if synergies disappoint, both further dilution and balance-sheet risk are real.
• Persistent GAAP margin/EPS compression from amortization and integration charges keeps the headline multiple elevated and sentiment weak.
• Product-liability litigation over preterm-infant specialty formulas (partially resolved, not fully).
• Competitive pressure in CGM (Dexcom, Medtronic) and diagnostics, plus FX and diabetes-care pricing pressure.
• Premium trailing valuation (32.8x TTM) leaves little cushion if execution slips, and the stock trades below all key moving averages, so momentum is fragile.

Abbott is a high-quality, diversified healthcare compounder going through a deliberately noisy transition. The ugly GAAP optics - Q2 2026 operating margin down to 14.2%, EPS halved to $0.53 - are acquisition accounting, not organic decay: comparable sales are guided to 6.5-7.5%, adjusted EPS guidance was raised to $5.45-$5.60, and cash flow remains strong (~$7.9B TTM FCF, 4.5% yield). At $101.96 (2026-09-13) the stock trades ~18.5x forward EPS with a clear gap to the $123.64 analyst target, but the Exact Sciences integration is unproven, leverage doubled, and the technicals are weak (RSI 33.6, below every moving average). This is a reasonable accumulate-on-weakness candidate for a patient investor rather than a table-pounding buy, and the fundamentals-plus-valuation combination nets to a Neutral directional lean.

Method: a 22x forward P/E applied to FY2026 adjusted EPS of ~$5.50 (midpoint of the raised $5.45-$5.60 guidance / $5.517 consensus) - a multiple justified by Abbott's premium-quality diversified medtech mix, low 0.586 beta and 2.78% dividend yield, but tempered for acquisition integration risk and $29.6B long-term debt. Cross-checks land nearby: ~15x forward EV/EBITDA implies ~$115 and ~4.7x P/S versus the 5-year average of 4.91x implies ~$126, so the ~$121 figure sits just below the $123.64 sell-side consensus and ~19% above the 2026-09-13 price of $101.96.